Back to search results

Study of Nab-Paclitaxel, Cisplatin, Gemcitabine, and Tumor Treatment Fields for Metastatic Pancreatic Cancer

This study is testing a new combination of treatments for metastatic pancreatic cancer (cancer that has spread to other parts of the body). It combines three chemotherapy drugs: nab-paclitaxel, cisplatin, and gemcitabine, with a device called Tumor Treatment Fields (TTF). TTF uses electric fields to disrupt cancer cell growth. The study aims to see how safe this combination is, with safety being measured after 28 days. You may be able to join if you are 18 or older and have pancreatic adenocarcinoma that has spread to the liver, even if it has spread to other areas (but not the brain). This is a small study, planning to enroll 40 participants, and its current status is unclear.

Study design
This is a Phase I/Ib, single-center study that is not randomized and is open-label. It plans to enroll 40 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety will be measured at 28 days after treatment begins.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04605913

Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC

Recruiting
PHASE1Ages 18+InterventionalTreatment
Mayo Clinic
~40 participants
Updated 2026-02-25 on ClinicalTrials.gov
What's tested:Modified GCN+TTF treatment

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety of (m)-GCN+TTF
Measured over 28 days

Conditions

Pancreas Cancer
Metastatic Pancreatic Cancer
Pancreatic Adenocarcinoma
Metastatic Adenocarcinoma

Explore related trials

Adenosquamous CarcinomaPancreatic Adenocarcinoma

NCT04605913

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic in Florida

    Jacksonville, Floridastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Hani M. Babiker, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Hepatic
Total bilirubin less than 1.5 X ULN;
alanine aminotransferase (ALT) or aspartate aminotransferase (AST) less than 3 X ULN.
Renal:
serum creatinine WNL or creatinine clearance greater than 50 mL/min. 5. QT intervals: QTc less than or equal to 470 msec for men and less than or equal to 490 msec for women. (As measured by Hodges' Equation: QTc = QT + 1.75(rate-60) where QTc = corrected QT interval and rate = ventricular rate/min). 6. Estimated life expectancy of at least 3 months 7. ECOG Performance Status 0-1. 8. Ability to operate the Novo TTF-100L (P) system. 9. Patients must have measurable disease on scans per RECIST 1.1. 10. Negative serum pregnancy test within 14 days prior to the first dose of study therapy for women of child-bearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally post-menopausal for at least 24 consecutive months (i.e., who has had menses any time in the preceding 24 consecutive months). Sexually active WCBP and male subjects must agree to use adequate methods to avoid pregnancy (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study and for 28 days after the completion of study treatment.

What this trial measures

  • Safety of (m)-GCN+TTF28 days

    Assessed by incidence of adverse events, as defined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.